These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 26960711)

  • 1. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer.
    Park MH; Kwon SY; Choi JE; Gong G; Bae YK
    Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
    Tian T; Ruan M; Yang W; Shui R
    Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
    Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
    Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
    Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
    J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
    Adams S; Gray RJ; Demaria S; Goldstein L; Perez EA; Shulman LN; Martino S; Wang M; Jones VE; Saphner TJ; Wolff AC; Wood WC; Davidson NE; Sledge GW; Sparano JA; Badve SS
    J Clin Oncol; 2014 Sep; 32(27):2959-66. PubMed ID: 25071121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.
    He TF; Yost SE; Frankel PH; Dagis A; Cao Y; Wang R; Rosario A; Tu TY; Solomon S; Schmolze D; Mortimer J; Lee P; Yuan Y
    PLoS One; 2020; 15(3):e0229955. PubMed ID: 32150594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of T lymphocytes infiltration in breast cancer].
    Yu HM; Jiao SC; Yang JL; Wang JD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):199-206. PubMed ID: 23643010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
    Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
    Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
    Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
    Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes and CD8
    Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.